Drug Addiction: From Basic Research to Therapy

Front Matter....Pages i-xxiii
DARPP-32 Mediates the Actions of Multiple Drugs of Abuse....Pages 3-16
Drug Discovery From Natural Sources....Pages 17-39
Computational Methods in Drug Design: Modeling G Protein-Coupled Receptor Monomers, Dimers, and Oligomers....Pages 41-68
Symbiotic Relationship of Pharmacogenetics and Drugs of Abuse....Pages 69-86
Monoclonal Antibody Form and Function: Manufacturing the Right Antibodies for Treating Drug Abuse....Pages 87-100
Cocaine- and Amphetamine-Regulated Transcript Peptides Play a Role in Drug Abuse and Are Potential Therapeutic Targets....Pages 101-112
RNAi-Directed Inhibition of DC-SIGN by Dendritic Cells: Prospects for HIV-1 Therapy....Pages 113-125
Viewing Chemokines as a Third Major System of Communication in the Brain....Pages 127-138
Targeting the PDZ Domains of Molecular Scaffolds of Transmembrane Ion Channels....Pages 139-148
Neuronal Nicotinic Acetylcholine Receptor Expression and Function on Nonneuronal Cells....Pages 149-166
Role of Monoamine Transporters in Mediating Psychostimulant Effects....Pages 169-177
Development of the Dopamine Transporter Selective RTI-336 as a Pharmacotherapy for Cocaine Abuse....Pages 179-191
Serotonin Transporters: Implications for Antidepressant Drug Development....Pages 193-215
Recent Advances for the Treatment of Cocaine Abuse: Central Nervous System Immunopharmacotherapy....Pages 217-229
κ Opioids as Potential Treatments for Stimulant Dependence....Pages 231-245
Regulation of Monoamine Transporters: Influence of Psychostimulants and Therapeutic Antidepressants....Pages 247-264
Hallucinogen Actions on 5-HT Receptors Reveal Distinct Mechanisms of Activation and Signaling by G Protein-Coupled Receptors....Pages 265-286
Recognition of Psychostimulants, Antidepressants, and Other Inhibitors of Synaptic Neurotransmitter Uptake by the Plasma Membrane Monoamine Transporters....Pages 287-309
Dual Dopamine/Serotonin Releasers as Potential Medications for Stimulant and Alcohol Addictions....Pages 311-326
Receptors of Mammalian Trace Amines....Pages 327-339
The Role of Crystallography in Drug Design....Pages 343-355
Opioid Peptide-Derived Analgesics....Pages 357-366
Opioid Ligands with Mixed μ/δ Opioid Receptor Interactions: An Emerging Approach to Novel Analgesics....Pages 367-380
Small-Molecule Agonists and Antagonists of the Opioid Receptor-Like Receptor (ORL1, NOP): Ligand-Based Analysis of Structural Factors Influencing Intrinsic Activity at NOP....Pages 381-394
Kappa Opioid Antagonists: Past Successes and Future Prospects....Pages 395-431
In Vitro and Direct In Vivo Testing of Mixture-Based Combinatorial Libraries for the Identification of Highly Active and Specific Opiate Ligands....Pages 433-453
Current Status of Immunologic Approaches to Treating Tobacco Dependence: Vaccines and Nicotine-Specific Antibodies....Pages 455-475
New Paradigms and Tools in Drug Design for Pain and Addiction....Pages 477-494
Neuropeptide-Processing Enzymes: Applications for Drug Discovery....Pages 497-509
CNS Drug Delivery: Opioid Peptides and the Blood-Brain Barrier....Pages 511-533
Cell-Permeable, Mitochondrial-Targeted, Peptide Antioxidants....Pages 535-546
Targeting Opioid Receptor Heterodimers: Strategies for Screening and Drug Development....Pages 547-558
Homology Modeling of Opioid Receptor-Ligand Complexes Using Experimental Constraints....Pages 559-584
Molecular Recognition of Opioid Receptor Ligands....Pages 585-608
Role of Morphine’s Metabolites in Analgesia: Concepts and Controversies....Pages 609-616
Mu Opioid Receptor Regulation and Opiate Responsiveness....Pages 617-624
Agmatine: Biological Role and Therapeutic Potentials in Morphine Analgesia and Dependence....Pages 625-634
The Therapeutic Potential of Drugs that Target Cannabinoid Receptors or Modulate the Tissue Levels or Actions of Endocannabinoids....Pages 637-686
Further Advances in the Synthesis of Endocannabinoid-Related Ligands....Pages 687-696
Ajulemic Acid (IP-751): Synthesis, Proof of Principle, Toxicity Studies, and Clinical Trials....Pages 697-706
Conformational Characteristics of the Interaction of SR141716A with the CB1 Cannabinoid Receptor as Determined Through the Use of Conformationally Constrained Analogs....Pages 707-718
Activation of G-Proteins in Brain by Endogenous and Exogenous Cannabinoids....Pages 719-729
2-Arachidonoylglycerol (2-AG) Membrane Transport: History and Outlook....Pages 731-736
Endocannabinoid Mechanisms of Pain Modulation....Pages 737-764
Back Matter....Pages 765-782